Exponent, Inc. (EXPO)
NEUTRALFundamental
65
Precio
$69.78
Capitalización Bursátil
$3.39B
Parte 1 · Cuánto vale la empresa
Resumen
Exponent, Inc., together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. It provides services in the areas of biomechanics, biomedical engineering and sciences, civil and structural engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, metallurgical and corrosion engineering polymer and chemistry, thermal sciences, and vehicle engineering. The company also offers services in the areas of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and health sciences. In addition, it provides proactive and reactive product safety, litigation support, and technical, regulatory services. It serves clients in chemical, construction, consumer products, energy, food, beverage and nutrition, government, life sciences, insurance, manufacturing, technology, industrial equipment, transportation, and other sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. The company was founded in 1967 and is headquartered in Menlo Park, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance y Liquidez
Ingresos
$632M
Últimos 12 meses (hasta 3/7/2026)
Beneficio Neto
$112M
Últimos 12 meses (hasta 3/7/2026)
Flujo de Caja Libre
$122M
Patrimonio Neto Total
$390M
Pasivo Total
$387M
Ratio de Liquidez
1.98
Cobertura de Intereses
-
Deuda/EBITDA
0.62
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$63.65
Precio Actual
$69.78
Margen de Seguridad
-9.6%
Rango de Valor Justo
$45.42 - $81.89
Métodos de Estimación
Métricas de Valoración
Ratio P/E
31.88
ROE
27.2%
Ratio P/B
11.66
P/FCF
31.00
Margen Bruto
-
ROIC
20.4%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
20.4%
WACC
8.1%
ROIC − WACC
+12.3 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Criterios de Análisis Fundamental
Superado (18)
- EPS shows upward trend
- Price CAGR 8.82%
- ROIC 20.4%
- Debt/Equity ratio
- Operating Margin 20.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 27.9%
- Revenue Growth 5Y 7.8%
- Analyst Consensus 80% Buy
- Earnings Surprise avg 4.3%
- Earnings Quality (OCF/NI) 1.06
- Share Dilution -0.9%
- Piotroski F-Score 5/9
Fallido (7)
- EPS CAGR 2.16%
- P/FCF 31.00
- P/B Ratio 11.66
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 4.90
- Net Margin Trend 17.7% vs 18.3%
No disponible (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Señales mixtas: algunas áreas requieren atención
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Dr. Catherine Ford Corrigan P.E., Ph.D. | CEO & Director | 56 |
| Mr. Richard L. Schlenker Jr. | Executive VP, Corporate Secretary & Director | 59 |
| Dr. Maureen T. F. Reitman F.S.P.E., P.E., Sc.D. | Group Vice President | 56 |
| Dr. Joseph Rakow Ph.D. | Group Vice President | 48 |
| Dr. Joseph Sala Ph.D. | Group Vice President | 48 |
| Dr. John D. Pye P.E., Ph.D. | President | 54 |
| Dr. Bernard Ross P.E., Ph.D. | Co-Founder & Principal Engineer | - |
| Mr. Eric R. Anderson | Chief Financial Officer | 50 |
| Ms. Gina Flynn | VP of Legal & General Counsel | - |
| Mr. Brian Kundert | Chief Human Resources Officer | 50 |
Riesgo de Auditoría
9
Riesgo del Consejo
2
Riesgo de Compensación
4
Riesgo de Derechos del Accionista
2
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for EXPO, sourced from Markets Gazette.